WOCKHARDT LTD. - 532300 - Compliance Certificate Under Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2022.
Compliance Certificate under Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 31st March, 2022. WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Change in Management
Pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations') read with Schedule III of Listing Regulations, we wish to inform you that the Board of Directors of the Company, at its meeting held today, accepted the request of Mr. Deepak Madnani to relinquish his responsibilities as the Chief Financial Officer of the Company and appointed Mr. Pramod Gupta as the new Chief Financial Officer of the Company with immediate effect. WOCKHARDT LTD. - 532300 - Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr. H. F Khorakiwala & Others WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We wish to inform you that the Company has issued an advertisement informing the basis of allotment of the Rights Issue in the following newspapers on 31st March, 2022: Financial Express (English - All editions) Jansatta (Hindi - All editions), and Navshakti (Marathi - Maharashtra) (Marathi being the regional language of Maharashtra, where the Company's registered office is situated). WOCKHARDT LTD. - 532300 - Closure of Trading Window
This is to inform you that pursuant to Company's 'Code of Conduct for regulating, monitoring and reporting trading by designated persons' ('the Code'), the Trading Window of the Company will be closed from 1st April, 2022 until 48 hours after the declaration of financial results of the Company for the quarter and year ended 31st March, 2022. WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Allotment
Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended w.r.t. allotment of 3,32,44,650 Equity Shares at a price of Rs. 225 per Equity Share (including a premium of Rs. 220 per Equity Share). WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Newspaper Publication
With reference to our letter dated March 4, 2022 for submitting the letter of offer dated March 4, 2022 ('Letter of Offer') in connection with the Issue and in continuation to our communication dated March 13, 2022 in connection with the advertisement issued under Regulation 84(1) of the SEBI ICDR Regulations, which included, among others, details of the date of completion of dispatch of the Abridged Letter of Offer and Application Form, and Addendum to the Letter of Offer; we hereby inform you that the Company has issued an advertisement informing addendum issued to the Letter of Offer, the Abridged Letter of Offer, Application Form and Rights Entitlement Letter ('Revised Advertisement'). We hereby submit the soft copy of the Revised Advertisement, in '.pdf' format.
Wockhardt unit partners with SII subsidiary to set up vaccine manufacturing plant in UK
According to a statement, the collaboration between Wockhardt UK and Serum Life Sciences UK Ltd will help create a considerable number of employment opportunities along with the creation of a new sterile fill and finish facility in Wrexham, North Wales. WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release dated 20th March, 2022 titled "Wockhardt and Serum Life Sciences UK announce collaboration for manufacturing multiple vaccines in the United Kingdom" WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Award of Order Receipt of Order
Wockhardt and Serum Life Sciences UK announce collaboration for manufacturing multiple vaccines in the United Kingdom